p-stat3

Stattic (STAT3 Inhibitor V) is a STAT3 inhibitor (IC50=5.1 μM) that selectively inhibits STAT3 activation, dimerization, and nuclear translocation. Stattic has antitumor activity and induces apoptosis.

Compound SC-1 is a a derivative of the multiple tyrosine kinase inhibitor sorafenib. Compound SC-1 potently inhibits the phosphorylation of STAT3 by blocking STAT3 phosphorylation and activation, and induces apoptosis in hepatocellular carcinoma cell lines[1].

STAT3-IN-32 (compound 4c) is an orally active, potent dual phosphorylation inhibitor of STAT3. It demonstrates significant inhibition of STAT3 luciferase activity in HEK293T cells, with an IC50 of 5.3 nM, and inhibits ATP production in BxPC-3 cells with an IC50 of 4.2 nM. By targeting the STAT3 SH2 domain (KD=21.3 nM), STAT3-IN-32 effectively blocks p-Tyr705 and p-Ser727, leading to the attenuation of STAT3 nuclear transcription and mitochondrial oxidative phosphorylation. Furthermore, this compound displays notable suppressive effects in a pancreatic cancer xenograft model.

MMT3-72 is a weak JAK1 inhibitor with superior efficacy and reduced p-STAT3 in DSS-induced colitis [1].

WR-S-462 is a STAT3 inhibitor. It effectively blocks the phosphorylation and biological functions of STAT3 in vitro. The IC50 of WR-S-462 for inhibiting MDA-MB-231 cells is 0.03 μM, and it exhibits a strong binding affinity for STAT3 protein with a Kd of 58 nM. WR-S-462 prevents the nuclear translocation of p-STAT3 and selectively inhibits the expression of p-STAT3Tyr705 in MDA-MB-231 cells, as well as the expression of downstream target genes regulated by STAT3, such as Cyclin D1, Bcl-2, and Bcl-xl. This compound inhibits the growth and metastasis of triple-negative breast cancer (TNBC).

JAK1 STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1 STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1 STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1 JAK1 and p-STAT3 STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).

Nifuroxazide-d4 is intended for use as an internal standard for the quantification of nifuroxazide by GC- or LC-MS. Nifuroxazide is a nitrofuran antibiotic. It is active against strains of the enteropathogenic bacteria C. jejuni, Salmonella, Y. enterocolitica, Shigella, and E. coli. It inhibits quorum sensing and virulence factor production in P. aeruginosa. Nifuroxazide inhibits STAT3 activity in a reporter assay and decreases viability of U266 and INA-6 myeloma cells, which have constitutive STAT3 phosphorylation, with EC50 values of approximately 4.5 µM for both. It also decreases viability, migration, and invasion of, and induces apoptosis in, MCF-7, 4T1, and MDA-MB-231 breast cancer cells. Nifuroxazide reduces tumor growth and prevents pulmonary metastasis in a 4T1 murine mammary carcinoma model. It also reduces diarrhea, weight loss, and colon inflammation in a rat model of acetic acid-induced ulcerative colitis.

(R)-Reticuline is a natural alkaloid that can be catalyzed by the microsomal P-450 system in plants and animals for conversion to Salutaridine, which is involved in endogenous morphine synthesis. The isomer of (R)-Reticuline is Reticuline. Reticuline inhibits the JAK2 STAT3 and NF-κB signaling pathways, and also inhibits the mRNA expression of TNF-α and IL-6, with anti-inflammatory effects.

SC-43 is a potent and orally active agonist of SHP-1 (PTPN6). SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis, and with anti-fibrotic and anticancer effects.

Garcinone D shows significant cytotoxicity against the CEM-SS cell line, with IC(50) value of 3.2 microg ml; it exhibits dose-dependent enzyme-based microsomal aromatase inhibitory activity. Garcinone D inhibits p65 activation with IC50 values of 3.2 micr

Solamargine (δ-Solanigrine) is a major steroidal alkaloid glycoside extracted from a traditional Chinese medicine herb, Solanum nigrum L. (SNL); has been shown to inhibit growth and induce apoptosis of various cancer cells.

ZX-29 is a potent and selective inhibitor of ALK with IC50 values of 2.1 nM, 1.3 nM, and 3.9 nM for ALK, ALK [L1196M], and ALK [G1202R] mutations, respectively. It also induces protective autophagy and exhibits antitumor effects.